NAGIOS: RODERIC FUNCIONANDO

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

dc.contributor.author	Provencio Pulla, Mariano
dc.contributor.author	Nadal, Ernest
dc.contributor.author	González Larriba, Jose Luís
dc.contributor.author	Martínez Martí, Alex
dc.contributor.author	Bernabé, Reyes
dc.contributor.author	Bosch Barrera, Joaquim
dc.contributor.author	Casal Rubio, Joaquín
dc.contributor.author	Calvo, Virginia
dc.contributor.author	Insa, Amelia
dc.contributor.author	Ponce, Santiago
dc.contributor.author	Reguart, Noemí
dc.contributor.author	De Castro, Javier
dc.contributor.author	Mosquera, Joaquín
dc.contributor.author	Cobo, Manuel
dc.contributor.author	Aguilar, Andrés
dc.contributor.author	López Vivanco, Guillermo
dc.contributor.author	Camps, Carlos
dc.contributor.author	López Castro, Rafael
dc.contributor.author	Morán, Teresa
dc.contributor.author	Barneto, Isidoro
dc.contributor.author	Rodríguez Abreu, Delvys
dc.contributor.author	Serna Blasco, Roberto
dc.contributor.author	Benítez, Raquel
dc.contributor.author	Aguado de la Rosa, Carlos
dc.contributor.author	Palmero, Ramón
dc.contributor.author	Hernando Trancho, Florentino
dc.contributor.author	Martín López, Javier
dc.contributor.author	Cruz Bermúdez, Alberto
dc.contributor.author	Massuti, Bartomeu
dc.contributor.author	Romero Alfonso, Atocha
dc.date.accessioned	2023-09-06T11:25:50Z
dc.date.available	2023-12-28T05:45:06Z
dc.date.issued	2023
dc.identifier.citation	Provencio Pulla, Mariano Nadal, Ernest González Larriba, Jose Luís Martínez Martí, Alex Bernabé, Reyes Bosch Barrera, Joaquim Casal Rubio, Joaquín Calvo, Virginia Insa, Amelia Ponce, Santiago Reguart, Noemí De Castro, Javier Mosquera, Joaquín Cobo, Manuel Aguilar, Andrés López Vivanco, Guillermo Camps, Carlos López Castro, Rafael Morán, Teresa Barneto, Isidoro Rodríguez Abreu, Delvys Serna Blasco, Roberto Benítez, Raquel Aguado de la Rosa, Carlos Palmero, Ramón Hernando Trancho, Florentino Martín López, Javier Cruz Bermúdez, Alberto Massuti, Bartomeu Romero Alfonso, Atocha 2023 Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer New England Journal of Medicine
dc.identifier.uri	https://hdl.handle.net/10550/89125
dc.description.abstract	BACKGROUND Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients. METHODS In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety. RESULTS A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P=0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan-Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%). CONCLUSIONS In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.
dc.language.iso	eng
dc.relation.ispartof	New England Journal of Medicine, 2023
dc.subject	Càncer
dc.title	Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
dc.type	journal article
dc.date.updated	2023-09-06T11:25:50Z
dc.identifier.doi	10.1056/NEJMoa2215530
dc.identifier.idgrec	161070
dc.embargo.terms	6 months
dc.rights.accessRights	open access